Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evolving Treatment of Hemophilia's Impact on Neurodevelopment, Intelligence and Other Cognitive Functions (eTHINK)

NCT03660774 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03660774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03660774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evolving Treatment of Hemophilia's Impact on Neurodevelopment, Intelligence and Other Cognitive Functions (eTHINK)
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
September 27, 2018
Completion date
October 11, 2019
Enrollment
563 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilia a, haemophilia b